| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ewa Kozela, Martyna Krawczyk, Tomasz Kos, Ana Juknat, Zvi Vogel, Piotr Popi. Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats. Molecular neurobiology. vol 57. issue 3. 2020-12-04. PMID:31823199. |
cannabidiol (cbd), a non-psychotropic cannabinoid, demonstrates antipsychotic-like and procognitive activities in humans and in animal models of schizophrenia. |
2020-12-04 |
2023-08-13 |
rat |
| Ritvij Satodiya, Nikhil Paleka. Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia. Cureus. vol 12. issue 9. 2020-10-20. PMID:33052290. |
synthetic cannabinoids and its association with persistent negative symptoms of schizophrenia. |
2020-10-20 |
2023-08-13 |
Not clear |
| Ritvij Satodiya, Nikhil Paleka. Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia. Cureus. vol 12. issue 9. 2020-10-20. PMID:33052290. |
synthetic cannabinoids (sc) commonly perpetuate the positive symptoms of schizophrenia. |
2020-10-20 |
2023-08-13 |
Not clear |
| Rafael N Ruggiero, Matheus T Rossignoli, Jana B De Ross, Jaime E C Hallak, Joao P Leite, Lezio S Bueno-Junio. Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. Frontiers in pharmacology. vol 8. 2020-09-30. PMID:28680405. |
cannabinoids and vanilloids in schizophrenia: neurophysiological evidence and directions for basic research. |
2020-09-30 |
2023-08-13 |
Not clear |
| Rafael N Ruggiero, Matheus T Rossignoli, Jana B De Ross, Jaime E C Hallak, Joao P Leite, Lezio S Bueno-Junio. Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. Frontiers in pharmacology. vol 8. 2020-09-30. PMID:28680405. |
much of our knowledge of the endocannabinoid system in schizophrenia comes from behavioral measures in rodents, like prepulse inhibition of the acoustic startle and open-field locomotion, which are commonly used along with neurochemical approaches or drug challenge designs. |
2020-09-30 |
2023-08-13 |
Not clear |
| Rafael N Ruggiero, Matheus T Rossignoli, Jana B De Ross, Jaime E C Hallak, Joao P Leite, Lezio S Bueno-Junio. Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. Frontiers in pharmacology. vol 8. 2020-09-30. PMID:28680405. |
in this sense, electrophysiology and viral vector-based circuit dissection, like optogenetics, can further elucidate how exogenous cannabinoids worsen (e.g., tetrahydrocannabinol, thc) or ameliorate (e.g., cannabidiol, cbd) schizophrenia symptoms, like hallucinations, delusions, and cognitive deficits. |
2020-09-30 |
2023-08-13 |
Not clear |
| Rose Chesworth, Leonora E Long, Cynthia Shannon Weickert, Tim Kar. The Endocannabinoid System across Postnatal Development in Transmembrane Domain Frontiers in psychiatry. vol 9. 2020-09-30. PMID:29467679. |
alterations to the endocannabinoid system have been found in the prefrontal cortex of patients with schizophrenia. |
2020-09-30 |
2023-08-13 |
mouse |
| Fabrizio Calapai, Luigi Cardia, Emanuela Elisa Sorbara, Michele Navarra, Sebastiano Gangemi, Gioacchino Calapai, Carmen Mannucc. Cannabinoids, Blood-Brain Barrier, and Brain Disposition. Pharmaceutics. vol 12. issue 3. 2020-09-28. PMID:32183416. |
finally, the potential role of cannabinoids in drug-resistance in the clinical management of neurological or psychiatric diseases such as epilepsy and schizophrenia is discussed on the light of their crossing the bbb. |
2020-09-28 |
2023-08-13 |
Not clear |
| Stéphane Potvin, Louiza Mahrouche, Roxane Assaf, Marjolaine Chicoine, Charles-Édouard Giguère, Alexandra Furtos, Roger Godbou. Peripheral Endogenous Cannabinoid Levels Are Increased in Schizophrenia Patients Evaluated in a Psychiatric Emergency Setting. Frontiers in psychiatry. vol 11. 2020-09-28. PMID:32695035. |
peripheral endogenous cannabinoid levels are increased in schizophrenia patients evaluated in a psychiatric emergency setting. |
2020-09-28 |
2023-08-13 |
Not clear |
| Stéphane Potvin, Louiza Mahrouche, Roxane Assaf, Marjolaine Chicoine, Charles-Édouard Giguère, Alexandra Furtos, Roger Godbou. Peripheral Endogenous Cannabinoid Levels Are Increased in Schizophrenia Patients Evaluated in a Psychiatric Emergency Setting. Frontiers in psychiatry. vol 11. 2020-09-28. PMID:32695035. |
while some studies have consistently shown that the levels of anandamide, an endogenous cannabinoid ligand, are increased in the cerebrospinal fluid of schizophrenia patients, inconsistent results have been observed in studies measuring anandamide levels in the periphery. |
2020-09-28 |
2023-08-13 |
Not clear |
| Ashleigh L Osborne, Nadia Solowij, Ilijana Babic, Jeremy S Lum, Kelly A Newell, Xu-Feng Huang, Katrina Weston-Gree. Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 95. 2020-08-26. PMID:31202911. |
effect of cannabidiol on endocannabinoid, glutamatergic and gabaergic signalling markers in male offspring of a maternal immune activation (poly i:c) model relevant to schizophrenia. |
2020-08-26 |
2023-08-13 |
rat |
| Ashleigh L Osborne, Nadia Solowij, Ilijana Babic, Jeremy S Lum, Kelly A Newell, Xu-Feng Huang, Katrina Weston-Gree. Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 95. 2020-08-26. PMID:31202911. |
therefore, the endocannabinoid system could represent a therapeutic target for schizophrenia as a regulator of glutamate and gaba release via the cb1 receptor (cb1r). |
2020-08-26 |
2023-08-13 |
rat |
| Carolina Muguruza, Benito Morentin, J Javier Meana, Stephen Ph Alexander, Luis F Callad. Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia. Journal of psychopharmacology (Oxford, England). vol 33. issue 9. 2020-08-12. PMID:31237179. |
endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia. |
2020-08-12 |
2023-08-13 |
human |
| Carolina Muguruza, Benito Morentin, J Javier Meana, Stephen Ph Alexander, Luis F Callad. Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia. Journal of psychopharmacology (Oxford, England). vol 33. issue 9. 2020-08-12. PMID:31237179. |
the endocannabinoid system - comprising cannabinoid receptors, endocannabinoid ligands and their synthesis and inactivation enzymes - has been widely implicated in the pathophysiology of schizophrenia. |
2020-08-12 |
2023-08-13 |
human |
| Carolina Muguruza, Benito Morentin, J Javier Meana, Stephen Ph Alexander, Luis F Callad. Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia. Journal of psychopharmacology (Oxford, England). vol 33. issue 9. 2020-08-12. PMID:31237179. |
we have previously reported altered endocannabinoid levels in the postmortem brain of subjects with schizophrenia compared with matched controls. |
2020-08-12 |
2023-08-13 |
human |
| Miquel Bioque, Sergi Mas, Maria Cristina Costanzo, Bibiana Cabrera, Antonio Lobo, Ana González-Pinto, Elisa Rodriguez-Toscano, Iluminada Corripio, Eduard Vieta, Immaculada Baeza, Ángela Ibáñez, Miguel Gutiérrez Fraile, Manuel J Cuesta, Gisela Mezquida, Amalia Lafuente, Miguel Bernard. Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 29. issue 6. 2020-08-07. PMID:31076188. |
alterations of the endocannabinoid system (ecs) may play an important role in the development of schizophrenia and other psychotic disorders. |
2020-08-07 |
2023-08-13 |
human |
| Valentin Y Skryabin, Maria A Vinnikov. Psychotic Disorders in Patients Who Use Synthetic Cannabinoids. Journal of psychiatric practice. vol 25. issue 6. 2020-06-29. PMID:31821228. |
the main objective of this study was to investigate the structure of psychotic disorders due to synthetic cannabinoid use and to determine differences in clinical characteristics and disease course between such substance-induced psychosis and psychosis associated with a primary diagnosis of schizophrenia. |
2020-06-29 |
2023-08-13 |
Not clear |
| Marta Kruk-Slomka, Izabela Banaszkiewicz, Tomasz Slomka, Grazyna Bial. Effects of Fatty Acid Amide Hydrolase Inhibitors Acute Administration on the Positive and Cognitive Symptoms of Schizophrenia in Mice. Molecular neurobiology. vol 56. issue 11. 2020-03-13. PMID:31004320. |
the connection between the endocannabinoid system (ecs) and schizophrenia is supported by a large body of research. |
2020-03-13 |
2023-08-13 |
mouse |
| Valéria Almeida, Raquel Levin, Fernanda Fiel Peres, Mayra Akimi Suiama, Ana Maria Vendramini, Camila Maurício Santos, Neide Derci Silva, Antonio Waldo Zuardi, Jaime Eduardo Cecílio Hallak, José Alexandre Crippa, Vanessa Costhek Abíli. Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit. Neuropharmacology. vol 155. 2020-02-28. PMID:31103618. |
studies suggest that the endocannabinoid and endovanilloid systems are implicated in the pathophysiology of schizophrenia. |
2020-02-28 |
2023-08-13 |
rat |
| Ferenc Zádor, Gábor Nagy-Grócz, Gabriella Kekesi, Szabolcs Dvorácskó, Edina Szűcs, Csaba Tömböly, Gyongyi Horvath, Sándor Benyhe, László Vécse. Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions. Molecules (Basel, Switzerland). vol 24. issue 20. 2020-02-20. PMID:31619006. |
kynurenines and the endocannabinoid system in schizophrenia: common points and potential interactions. |
2020-02-20 |
2023-08-13 |
Not clear |